Proactive - Interviews for investors
Just the Facts: Tryptamine Therapeutics successfully completes Phase 1b Study of TRP-8803 in obese patients
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Tryptamine Therapeutics Limited (ASX: TYP).
Tryp has concluded its Phase 1b study of TRP-8803, an IV-infused psilocin-based formulation, in obese participants.
Conducted at CMAX Clinical Research in Adelaide, the trial safely administered the treatment to three participants over a 140-minute period, completing the study within a week.
This rapid timeframe highlights the formulation’s scalability and potential.
TRP-8803 is designed to provide neuroplastic benefits, with applications for adaptive brain changes linked to psychiatric improvements.
The study generated valuable human data to optimise dosing for upcoming Phase 2 trials, targeting weight-related conditions such as Binge Eating Disorder.
Results, expected by the year’s end, will guide the advanced planning of the Phase 2 program. Tryptamine noted that all participants were safely discharged post-administration, marking a significant milestone in demonstrating the formulation’s potential to deliver improved health outcomes efficiently.
The company emphasises TRP-8803’s broad research opportunities and looks forward to leveraging the final dataset to explore its efficacy in addressing unmet medical needs within large market opportunities.
#ProactiveInvestors #TrypTherapeutics #ASX #JusttheFacts #TRP8803, #ClinicalTrials, #PsilocinResearch, #Neuroplasticity, #BingeEatingDisorder, #IVTherapy, #ObesityResearch, #DrugDevelopment, #MentalHealthTreatment, #PsilocybinTherapy, #HealthInnovation, #CMAXResearch, #PharmaceuticalInnovation, #ClinicalStudy, #WeightManagement, #Biopharma, #Phase2Trials, #MedicalBreakthroughs, #TherapeuticResearch
- Duration:
- 1m
- Broadcast on:
- 29 Nov 2024
- Audio Format:
- other
Hello and welcome to this episode of proactive's just effects. I'm your host, Tyler Tully. Trip to Meet Therapeutics has successfully concluded its phase 1B study of TRP8803 in obese patients. The IV-infused cellulose and base formulation was safely administered to three participants from the obese population for over 140 minutes. The trial was conducted by CMAC's clinical research in Adelaide and was completed within only one week demonstrating the scalability and potential of the formulation. TRP8803 is an innovative formulation with potential neuroplastic benefits. Neuroplastic pharmaceuticals are known to cause adaptive structural and functional changes in the brain and are associated with clinical improvements in a range of psychiatric illnesses. This cost-effective study generated valuable human data, supporting dose optimization for future phase 2 trials and dilute related conditions such as binge eating disorder. Results expected by the year's end will inform the phase 2 clinical program, which is currently under advanced planning. The company says to have completed subject dosing over such a short time frame is a great achievement and also highlights the considerable potential for future research opportunities using TRP8803. All subjects that underwent treatment did so safely and they were all discharged after administration, marking the achievement of an important early stage clinical objective and also confirming the potential of TRP8803 to deliver improved health outcomes in a timely manner. Chip looks forward to receiving the final data set from CMAC's which will assist in ongoing planning for its phase 2 trials to explore the efficacy of the application over specific unmet need states with large addressable market opportunities. Thanks for watching, these are just the facts.
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Tryptamine Therapeutics Limited (ASX: TYP).
Tryp has concluded its Phase 1b study of TRP-8803, an IV-infused psilocin-based formulation, in obese participants.
Conducted at CMAX Clinical Research in Adelaide, the trial safely administered the treatment to three participants over a 140-minute period, completing the study within a week.
This rapid timeframe highlights the formulation’s scalability and potential.
TRP-8803 is designed to provide neuroplastic benefits, with applications for adaptive brain changes linked to psychiatric improvements.
The study generated valuable human data to optimise dosing for upcoming Phase 2 trials, targeting weight-related conditions such as Binge Eating Disorder.
Results, expected by the year’s end, will guide the advanced planning of the Phase 2 program. Tryptamine noted that all participants were safely discharged post-administration, marking a significant milestone in demonstrating the formulation’s potential to deliver improved health outcomes efficiently.
The company emphasises TRP-8803’s broad research opportunities and looks forward to leveraging the final dataset to explore its efficacy in addressing unmet medical needs within large market opportunities.
#ProactiveInvestors #TrypTherapeutics #ASX #JusttheFacts #TRP8803, #ClinicalTrials, #PsilocinResearch, #Neuroplasticity, #BingeEatingDisorder, #IVTherapy, #ObesityResearch, #DrugDevelopment, #MentalHealthTreatment, #PsilocybinTherapy, #HealthInnovation, #CMAXResearch, #PharmaceuticalInnovation, #ClinicalStudy, #WeightManagement, #Biopharma, #Phase2Trials, #MedicalBreakthroughs, #TherapeuticResearch